{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:20:28Z","timestamp":1792189228513,"version":"4.4.0"},"reference-count":260,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n          <jats:p>New antimicrobial agents are always needed to counteract the resistant pathogens that continue to be selected by current therapeutic regimens. This review provides a survey of known antimicrobial agents that were currently in clinical development in the fall of 2012 and spring of 2013. Data were collected from published literature primarily from 2010 to 2012, meeting abstracts (2011 to 2012), government websites, and company websites when appropriate. Compared to what was reported in previous surveys, a surprising number of new agents are currently in company pipelines, particularly in phase 3 clinical development. Familiar antibacterial classes of the quinolones, tetracyclines, oxazolidinones, glycopeptides, and cephalosporins are represented by entities with enhanced antimicrobial or pharmacological properties. More importantly, compounds of novel chemical structures targeting bacterial pathways not previously exploited are under development. Some of the most promising compounds include novel \u03b2-lactamase inhibitor combinations that target many multidrug-resistant Gram-negative bacteria, a critical medical need. Although new antimicrobial agents will continue to be needed to address increasing antibiotic resistance, there are novel agents in development to tackle at least some of the more worrisome pathogens in the current nosocomial setting.<\/jats:p>","DOI":"10.1128\/cmr.00033-13","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T19:42:30Z","timestamp":1380829350000},"page":"792-821","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":91,"title":["Investigational Antimicrobial Agents of 2013"],"prefix":"10.1128","volume":"26","author":[{"given":"Michael J.","family":"Pucci","sequence":"first","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bush","sequence":"additional","affiliation":[{"name":"Indiana University, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(10)00497-8"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70316-4"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2010.01.007"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s000180050021"},{"key":"e_1_3_2_7_2","unstructured":"Chan\nM\n. 14 March 2012 posting date. Antimicrobial resistance in the European Union and the world. \nhttp:\/\/www.who.int\/dg\/speeches\/2012\/amr_20120314\/en\/."},{"key":"e_1_3_2_8_2","unstructured":"Shlaes\nDM\n. 4 September 2012. New antibiotics? Go public!\nhttp:\/\/antibiotics-theperfectstorm.blogspot.com\/2012\/09\/new-antibiotics-go-public.html\n."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2011.44"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.07.077"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06323.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit152"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2012.06.003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp486"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-011-3557-z"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2010.505922"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr030101q"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01197-09"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-09"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00295-10"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0205090"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks307"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2771-2777.2004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3260-3269.2003"},{"key":"e_1_3_2_25_2","volume-title":"Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects","author":"Lawrence L","year":"2011","unstructured":"Lawrence L Benedict M Hart J Hawkins A Li D Medlock M Hopkins S Burak E . 2011. Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr A2-045."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-10"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq375"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01637-09"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01407-05"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1081\/DCT-200039708"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00162-11"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01374-09"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05044-11"},{"key":"e_1_3_2_34_2","volume-title":"DS-8587, a new generation of broad spectrum quinolone: antibacterial spectrum and its in vitro activity against clinical isolates in Japan","author":"Chiba M","year":"2012","unstructured":"Chiba M Fujikawa K Okumura R Yuichi K Hoshino K . 2012. DS-8587, a new generation of broad spectrum quinolone: antibacterial spectrum and its in vitro activity against clinical isolates in Japan. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. abstr F-2037."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02374-12"},{"key":"e_1_3_2_36_2","volume-title":"DS-8587, a new generation of broad spectrum quinolone: pharmacodynamic and therapeutic efficacy in animal infection models","author":"Kurosaka Y","year":"2012","unstructured":"Kurosaka Y Ubyama S Ishii K Hoshino K . 2012. DS-8587, a new generation of broad spectrum quinolone: pharmacodynamic and therapeutic efficacy in animal infection models. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. abstr F-2035."},{"key":"e_1_3_2_37_2","volume-title":"DS-8587, a new generation of broad spectrum quinolone: safety profile in preclinical studies","author":"Miida H","year":"2012","unstructured":"Miida H Tsuchiya Y Itoh S Noritake K Ishizawa T Takasaki W . 2012. DS-8587, a new generation of broad spectrum quinolone: safety profile in preclinical studies. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. abstr F-2042."},{"key":"e_1_3_2_38_2","volume-title":"KPI-10, a novel fluoroquinolone (FQ) tested against Neisseria gonorrhoeae including ciprofloxacin non-susceptible (CIP-NS) and penicillin non-susceptible (PEN-NS) strains","author":"Flamm RK","year":"2012","unstructured":"Flamm RK Biedenbach DJ Sader HS Konrardy ML Jones RN . 2012. KPI-10, a novel fluoroquinolone (FQ) tested against Neisseria gonorrhoeae including ciprofloxacin non-susceptible (CIP-NS) and penicillin non-susceptible (PEN-NS) strains. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2052."},{"key":"e_1_3_2_39_2","volume-title":"In vitro activity of KPI-10 against clinically important Gram-negative bacteria","author":"Deane J","year":"2012","unstructured":"Deane J Simenauer A Ge Y Eckburg PB Sahm D . 2012. In vitro activity of KPI-10 against clinically important Gram-negative bacteria. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2046."},{"key":"e_1_3_2_40_2","volume-title":"In vitro activity of KPI-10 against clinically important Gram-negative bacteria","author":"Deane J","year":"2012","unstructured":"Deane J Simenauer A Ge Y Eckburg PB Sahm D . 2012. In vitro activity of KPI-10 against clinically important Gram-negative bacteria. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2047."},{"key":"e_1_3_2_41_2","volume-title":"Safety & pharmacokinetics of KPI-10, a novel fluoroquinolone, in healthy adults receiving single-dose oral administrations","author":"Eckburg PB","year":"2012","unstructured":"Eckburg PB Ge Y Jiang V Kilfoil T Talbot GH . 2012. Safety & pharmacokinetics of KPI-10, a novel fluoroquinolone, in healthy adults receiving single-dose oral administrations. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. abstr F-2047."},{"key":"e_1_3_2_42_2","volume-title":"Ozenoxacin. Activity against Gram-positive bacteria (GPB) causing skin and soft tissue infections (SSTI) collected in 2009-10","author":"Morrissey I","year":"2012","unstructured":"Morrissey I Janes R Dallow J Leakey A Gugliett A Gargallo-Viola D . 2012. Ozenoxacin. Activity against Gram-positive bacteria (GPB) causing skin and soft tissue infections (SSTI) collected in 2009-10. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr B-1302."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000337084"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr557"},{"key":"e_1_3_2_45_2","first-page":"379","article-title":"Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones","volume":"14","author":"Chu DT","year":"1988","unstructured":"Chu DT Fernandes PB Claiborne AK Shen L Pernet AG . 1988. Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones. Drugs Exp. Clin. Res. 14:379\u2013383.","journal-title":"Drugs Exp. Clin. Res."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01315-06"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01666-10"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1946.tb31756.x"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/327389a0"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.650"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00572-10"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2010.09.004"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00556-09"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq408"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.05.016"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq459"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00862-10"},{"key":"e_1_3_2_58_2","volume-title":"Efficacy of plazomicin against Yersinia pestis in a murine-aerosol challenge late-treatment model","author":"Heine HS","year":"2012","unstructured":"Heine HS Chuvala L Riggins R Hurteau G Cass R Cirz R . 2012. Efficacy of plazomicin against Yersinia pestis in a murine-aerosol challenge late-treatment model. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr B-1302."},{"key":"e_1_3_2_59_2","volume-title":"Efficacy of intravenous plazomicin in the African green monkey (AGM) inhalational plague model","author":"Mega W","year":"2012","unstructured":"Mega W Cirz R Cass R Reyes N Valderas M Sherwood R . 2012. Efficacy of intravenous plazomicin in the African green monkey (AGM) inhalational plague model. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr B-1308a."},{"key":"e_1_3_2_60_2","volume-title":"Pharmacodynamics of plazomicin in a neutropenic murine pneumonia model against Klebsiella pneumoniae (Kpn)","author":"Louie A","year":"2012","unstructured":"Louie A Fikes S Liu W VanScoy B Cirz R Drusano G . 2012. Pharmacodynamics of plazomicin in a neutropenic murine pneumonia model against Klebsiella pneumoniae (Kpn). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-041."},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-11"},{"key":"e_1_3_2_62_2","volume-title":"Plazomicin safety and efficacy in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)","author":"Riddle V","year":"2012","unstructured":"Riddle V Cebrik D Armstrong E Cass R Clobes T Hillan K Crofton . 2012. Plazomicin safety and efficacy in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr L-2118a."},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06354.x"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(99)00216-4"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.738"},{"key":"e_1_3_2_66_2","volume-title":"In vitro activity of PTK0796 (BAY 73-6944) against Gram-positive and Gram-negative organisms","author":"Macone A","year":"2003","unstructured":"Macone A Donatelli J Dumont T Levy SB Tanaka SK . 2003. In vitro activity of PTK0796 (BAY 73-6944) against Gram-positive and Gram-negative organisms. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr 2439."},{"key":"e_1_3_2_67_2","volume-title":"PTK 0796 (BAY 73-6944): in vitro potency and spectrum of activity compared to ten other antimicrobial compounds","author":"Traczewski MM","year":"2003","unstructured":"Traczewski MM Brown SD . 2003. PTK 0796 (BAY 73-6944): in vitro potency and spectrum of activity compared to ten other antimicrobial compounds, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr 2458."},{"key":"e_1_3_2_68_2","volume-title":"Omadacycline (PTK796) mechanism of action studies by using in vitro protein synthesis inhibition assay and molecular modeling","author":"Ruzin A","year":"2011","unstructured":"Ruzin A Petrone P Whitehead L Bradford PA . 2011. Omadacycline (PTK796) mechanism of action studies by using in vitro protein synthesis inhibition assay and molecular modeling. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr C1-609."},{"key":"e_1_3_2_69_2","volume-title":"The activity of PTK0796 against tetracycline resistance","author":"Weir S","year":"2003","unstructured":"Weir S Macone A Donatelli J Trieber C Taylor DE Tanaka SK Levy SB . 2003. The activity of PTK0796 against tetracycline resistance. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-752."},{"key":"e_1_3_2_70_2","volume-title":"Studies on the mechanism of resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae","author":"Ruzin A","year":"2010","unstructured":"Ruzin A Dzink-Fox J Jones AK Dean CR Bradford PA . 2010. Studies on the mechanism of resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae . Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr C1-1079."},{"key":"e_1_3_2_71_2","volume-title":"Pharmacokinetics of [14c]-labeled omadacycline (PTK 0796) in healthy male subjects","author":"Sun H","year":"2012","unstructured":"Sun H Ting L Flarakos J Dole K Praestgaard J Kovacs SJ Stein DS Sunkara G Tanaka SK . 2012. Pharmacokinetics of [14c]-labeled omadacycline (PTK 0796) in healthy male subjects. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-1281."},{"key":"e_1_3_2_72_2","volume-title":"Identification and susceptibility of pathogens isolated from patients with complicated skin and skin structure infections (cSSSI): results of a PTK 0796 (PTK) phase 2 clinical trial","author":"Macone AB","year":"2010","unstructured":"Macone AB Arbeit RD Hait HI Draper MP Tanaka SK . 2010. Identification and susceptibility of pathogens isolated from patients with complicated skin and skin structure infections (cSSSI): results of a PTK 0796 (PTK) phase 2 clinical trial. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr L1-1760."},{"key":"e_1_3_2_73_2","volume-title":"Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli","author":"O'Brien W","year":"2012","unstructured":"O'Brien W Sutcliffe J Grossman T . 2012. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr E-777."},{"key":"e_1_3_2_74_2","volume-title":"Efficacy and safety of TP-434 versus ertapenem in complicated intra-abdominal infection (cIAI)","author":"Horn P","year":"2012","unstructured":"Horn P Cesnauskas G Ramesh M Walpole S Sutcliffe J Solomkin J . 2012. Efficacy and safety of TP-434 versus ertapenem in complicated intra-abdominal infection (cIAI). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr L1-1647a."},{"key":"e_1_3_2_75_2","volume-title":"TP-271 is a potent, broad-spectrum fluorocycline with activity against community-acquired bacterial respiratory and biothreat pathogens","author":"Grossman TH","year":"2012","unstructured":"Grossman TH Fyfe C Brien WO Hackel M Sutcliffe JA . 2012. TP-271 is a potent, broad-spectrum fluorocycline with activity against community-acquired bacterial respiratory and biothreat pathogens. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1525."},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1007988107"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60219-5"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568005014606071"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2999-3002.2000"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06300.x"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1562-1567.2000"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.3.290"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R435"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02316-12"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2010.08.010"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.08.021"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00840-10"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01429-10"},{"key":"e_1_3_2_89_2","first-page":"271","volume-title":"Oxazolidinone antibacterial agents","author":"Barbachyn MR","year":"2012","unstructured":"Barbachyn MR . 2012. Oxazolidinone antibacterial agents, p 271\u2013299. In Dougherty TJ Pucci MJAntibacterial drug discovery and development . Springer Publishers, New York, NY."},{"key":"e_1_3_2_90_2","unstructured":"Fugitt\nRB\nLuckenbaugh\nRW\n. December 1978. 5-Halomethyl-3-phenyl-2-oxazolidinones. US patent 4 128 654."},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06330.x"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.11.1791"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00128a003"},{"key":"e_1_3_2_94_2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1021\/jm00171a035","article-title":"Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2","volume":"33","author":"Gregory WA","year":"1990","unstructured":"Gregory WA Brittelli DR Wang C-LJ Kezar HS III Carlson RK Park CH Corless PF Miller SJ Rajagopalan P . 1990. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The \u201cA\u201d group. J. Med. Chem. 33:2569\u20132578.","journal-title":"The \u201cA\u201d group. J. Med. Chem."},{"key":"e_1_3_2_95_2","first-page":"1156","article-title":"Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxazolidinones. 4","volume":"35","author":"Park CH","year":"1992","unstructured":"Park CH Brittelli DR Wang C-L Marsh FD Gregory WA Wuonola MA McRipley RJ Eberly VS Slee AM Forbes M . 1992. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxazolidinones. 4. Multiply-substituted aryl derivatives. J. Med. Chem. 35:1156\u20131165.","journal-title":"Multiply-substituted aryl derivatives. J. Med. Chem."},{"key":"e_1_3_2_96_2","first-page":"379","article-title":"A critical review of oxazolidinones: An alternative or replacement for glycopeptides and streptogramins?","volume":"12","author":"Zhanel GG","year":"2001","unstructured":"Zhanel GG Schroeder C Vercaigne L Gin AS Embil J Hoban DJ . 2001. A critical review of oxazolidinones: An alternative or replacement for glycopeptides and streptogramins? Can. J. Infect. Dis. 12:379\u2013390.","journal-title":"Can. J. Infect. Dis."},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568005014606099"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026033452195"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2007.05744.x"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1086\/501356"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01190-06"},{"key":"e_1_3_2_102_2","author":"Das D","year":"2012","unstructured":"Das D Lambert A Tulkens PM Muccioli GG Van Bambeke F . 2012. Study of the cellular uptake and subcellular distribution of the oxazolidinone tedizolid (TZD) in murine J774 macrophages: lack of association with mitochondria. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-1291.","journal-title":"Study of the cellular uptake and subcellular distribution of the oxazolidinone tedizolid (TZD) in murine J774 macrophages: lack of association with mitochondria"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01383-07"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00663-10"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01723-09"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01724-09"},{"key":"e_1_3_2_107_2","volume-title":"Antibacterial spectrum of oxazolidinone MRX-1: potent activity against multidrug-resistant Gram-positive pathogens","author":"Zhu DM","year":"2012","unstructured":"Zhu DM Wang W Huang YQ Zhang YY . 2012. Antibacterial spectrum of oxazolidinone MRX-1: potent activity against multidrug-resistant Gram-positive pathogens. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1497."},{"key":"e_1_3_2_108_2","volume-title":"Novel oxazolidinone MRX-1 is efficacious in mouse models of Gram-positive bacterial infections","author":"Li CR","year":"2012","unstructured":"Li CR Li GQ Hu XX Zhang WX Wang XK Pang J Lu X Zhai QQ Yuan H Gordeev MF Yang XY You XF . 2012. Novel oxazolidinone MRX-1 is efficacious in mouse models of Gram-positive bacterial infections. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1499."},{"key":"e_1_3_2_109_2","volume-title":"Single oral dose pharmacokinetics of MRX-1 in healthy subjects","author":"Zhang J","year":"2012","unstructured":"Zhang J Wu XJ Huang J Yu JC Guo BN Cao GY Wu JF Zhang KJ Yuan H Yuan ZY Shi YG Zhang YY . 2012. Single oral dose pharmacokinetics of MRX-1 in healthy subjects. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1503."},{"key":"e_1_3_2_110_2","volume-title":"Hematological effect and pharmacokinetics of multiple oral dose MRX-1 in healthy subjects","author":"Zhang J","year":"2012","unstructured":"Zhang J Wu XJ Huang J Yu JC Guo BN Cao GY Wu JF Yuan H Yuan ZY Shi YG Zhang YY . 2012. Hematological effect and pharmacokinetics of multiple oral dose MRX-1 in healthy subjects. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1503."},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00723-10"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf068"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1086\/499365"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.37.9.570"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.2174\/138955712798868968"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1975.tb03976.x"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-351"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01390-09"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06219.x"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.2174\/138955709789957387"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00178-06"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05789-11"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks001"},{"key":"e_1_3_2_124_2","volume-title":"A phase 2 study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in acute bacterial skin and skin structure infections (ABSSSI)","author":"Prince WT","year":"2011","unstructured":"Prince WT Obermayr F Ivezic-Schoenfeld Z Lell C Wicha WW Strickmann DB Tack KJ Novak R . 2011. A phase 2 study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in acute bacterial skin and skin structure infections (ABSSSI). Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr L-966."},{"key":"e_1_3_2_125_2","volume-title":"In vitro antibacterial spectrum of BC-7013, a novel pleuromutilin derivative for topical use in humans","author":"Biedenbach DJ","year":"2009","unstructured":"Biedenbach DJ Jones RN Ivezic-Schoenfeld Z Paukner S Novak R . 2009. In vitro antibacterial spectrum of BC-7013, a novel pleuromutilin derivative for topical use in humans. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. abstr F1-1521."},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12023"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12024"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01525-09"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp425"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr013"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.172.3.1361-1367.1990"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1010"},{"key":"e_1_3_2_133_2","author":"Gould JK","year":"2013","unstructured":"Gould JK Sattar A Thommes P Payne LJ Stubbings W Spickermann J Daws G Warn P . 2013. Efficacy of BAL30072 in murine thigh infection models of multi-resistant Gram-negative bacteria. Abstr. Eur. Congr. Clin. Microbiol. Infect. Dis, abstr P 908.","journal-title":"Efficacy of BAL30072 in murine thigh infection models of multi-resistant Gram-negative bacteria"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00604a024"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.4.851"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1211"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-06"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq248"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.02.004"},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.03.021"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00568-10"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205073109"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01722-10"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn320"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-09"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.012"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01696-10"},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq306"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06064-11"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-10"},{"key":"e_1_3_2_153_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00372-11"},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq161"},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01787-10"},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00817-12"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks079"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_2_159_2","volume-title":"In vitro activity of the class A and C \u03b2-lactamase inhibitor MK-7655","author":"Young K","year":"2010","unstructured":"Young K Raghoobar SL Hairston NN Painter RE Racine F Dorson KL Hermes JD Hammond ML Motyl MR . 2010. In vitro activity of the class A and C \u03b2-lactamase inhibitor MK-7655. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr F1-2139."},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.1021\/ol202195n"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05927-11"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06113-11"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.5.949"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01964439"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.1.75"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-010-0112-2"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(95)80008-2"},{"key":"e_1_3_2_168_2","volume-title":"Discovery of RPX7009, a broad-spectrum beta-lactamase inhibitor with utility vs. class A serine carbapenemases","author":"Hecker SJ","year":"2012","unstructured":"Hecker SJ Reddy KR Totrov M Hirst GC Lomovskaya O Griffith DC King P Tsivkovski R Sun D Sabet M Taraz Z Dudley MN . 2012. Discovery of RPX7009, a broad-spectrum beta-lactamase inhibitor with utility vs. class A serine carbapenemases. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. http:\/\/www.icaac.org\/ ."},{"key":"e_1_3_2_169_2","volume-title":"Biochemical characterization of the beta-lactamase inhibitor RPX7009","author":"Lomovskaya O","year":"2012","unstructured":"Lomovskaya O Tsivkovsky R Griffith D Hecker SJ Dudley MN . 2012. Biochemical characterization of the beta-lactamase inhibitor RPX7009. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-849."},{"key":"e_1_3_2_170_2","volume-title":"In vivo efficacy of the beta-lactamase inhibitor RPX7009 combined with the carbapenem RPX2003 against KPC-producing K. pneumoniae","author":"Sabet M","year":"2012","unstructured":"Sabet M Tarazi Z Lomovskaya O Hecker SJ Dudley MN Griffith DC . 2012. In vivo efficacy of the beta-lactamase inhibitor RPX7009 combined with the carbapenem RPX2003 against KPC-producing K. pneumoniae . Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-858."},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2012.04.018"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1110\/ps.8.11.2330"},{"key":"e_1_3_2_173_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.02.065"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00930-10"},{"key":"e_1_3_2_175_2","volume-title":"Nonclinical toxicology and safety profile of the beta-lactamase inhibitor RPX7009","author":"Griffith DC","year":"2012","unstructured":"Griffith DC Sabet M Tarazi Z Tsivkovski R Lomovskaya O Hecker SJSJ Dudley MN . 2012. Nonclinical toxicology and safety profile of the beta-lactamase inhibitor RPX7009. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. http:\/\/www.icaac.org\/ ."},{"key":"e_1_3_2_176_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.15.5449"},{"key":"e_1_3_2_177_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010611-134535"},{"key":"e_1_3_2_178_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules171012276"},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05009-11"},{"key":"e_1_3_2_180_2","volume-title":"The activity of PMX-30063 against staphylococci and streptococci","author":"Morrisey I","year":"2012","unstructured":"Morrisey I Dallow J Siegwart E Smith A Scott R Korczak B . 2012. The activity of PMX-30063 against staphylococci and streptococci. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis., abstr P-1458."},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1182749"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201200276"},{"key":"e_1_3_2_183_2","volume-title":"Phase 1 study with the novel Pseudomonas aeruginosa antibiotic POL7080 in healthy volunteers","author":"Wilbraham S","year":"2011","unstructured":"Wilbraham S DeMarco S Ograbek A Agren J Wach A Obrecht D Demkowski K . 2011. Phase 1 study with the novel Pseudomonas aeruginosa antibiotic POL7080 in healthy volunteers. Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis.-27th Int. Congr. Chemother. abstr P 1513."},{"key":"e_1_3_2_184_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir475"},{"key":"e_1_3_2_185_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2011.23.4.200"},{"key":"e_1_3_2_186_2","doi-asserted-by":"publisher","DOI":"10.1086\/659152"},{"key":"e_1_3_2_187_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr066"},{"key":"e_1_3_2_188_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01152-11"},{"key":"e_1_3_2_189_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.05.012"},{"key":"e_1_3_2_190_2","first-page":"229","article-title":"Dalbavancin (Biosearch Italia\/Versicor)","volume":"3","author":"Steiert M","year":"2002","unstructured":"Steiert M Schmitz FJ . 2002. Dalbavancin (Biosearch Italia\/Versicor). Curr. Opin. Invest. Drugs 3:229\u2013233.","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"e_1_3_2_191_2","first-page":"1039","article-title":"Oritavancin","volume":"2","author":"Barrett JF","year":"2001","unstructured":"Barrett JF . 2001. Oritavancin. Eli Lilly & Co. Curr. Opin. Invest. Drugs 2:1039\u20131044.","journal-title":"Eli Lilly & Co. Curr. Opin. Invest. Drugs"},{"key":"e_1_3_2_192_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.3.379"},{"key":"e_1_3_2_193_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg457"},{"key":"e_1_3_2_194_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.179"},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2003.tb00628.x"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.2165\/11534440-000000000-00000"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00029-11"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi992245y"},{"key":"e_1_3_2_199_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(02)00549-1"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(03)00596-5"},{"key":"e_1_3_2_201_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M309770200"},{"key":"e_1_3_2_202_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867054367194"},{"key":"e_1_3_2_203_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2201"},{"key":"e_1_3_2_204_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.250-261.2004"},{"key":"e_1_3_2_205_2","volume-title":"In vitro activity of GSK1322322, a novel peptide deformylase inhibitor, against 4,836 pathogens from skin and soft tissue infections and respiratory tract infections","author":"Bouchillon S","year":"2010","unstructured":"Bouchillon S Hackel M Hoban D Zalacain M Butler D . 2010. In vitro activity of GSK1322322, a novel peptide deformylase inhibitor, against 4,836 pathogens from skin and soft tissue infections and respiratory tract infections. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr F1-2112."},{"key":"e_1_3_2_206_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01213-11"},{"key":"e_1_3_2_207_2","volume-title":"Penetration of GSK1322322 (GSK322) into epithelial lining fluid (ELF) and alveolar macrophages (AM) as determined by bronchoalveolar lavage (BAL)","author":"Naderer OJ","year":"2012","unstructured":"Naderer OJ Rodvold KA Jones LS Zhu JZ Dumont EF . 2012. Penetration of GSK1322322 (GSK322) into epithelial lining fluid (ELF) and alveolar macrophages (AM) as determined by bronchoalveolar lavage (BAL). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. http:\/\/www.icaac.org\/ ."},{"key":"e_1_3_2_208_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3343-3347.2002"},{"key":"e_1_3_2_209_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568005054880154"},{"key":"e_1_3_2_210_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0705354"},{"key":"e_1_3_2_211_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01248-10"},{"key":"e_1_3_2_212_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm301113w"},{"key":"e_1_3_2_213_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2006.10.012"},{"key":"e_1_3_2_214_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-8-61"},{"key":"e_1_3_2_215_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.07.094"},{"key":"e_1_3_2_216_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.07.129"},{"key":"e_1_3_2_217_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00400-09"},{"key":"e_1_3_2_218_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01411-12"},{"key":"e_1_3_2_219_2","volume-title":"MUT056399: a single intravenous ascending dose study in healthy human volunteers","author":"Soulama C","year":"2010","unstructured":"Soulama C Bryskier A Chassard D Fischer S . 2010. MUT056399: a single intravenous ascending dose study in healthy human volunteers. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr 1969."},{"key":"e_1_3_2_220_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0277"},{"key":"e_1_3_2_221_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2012.02.033"},{"key":"e_1_3_2_222_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88266-1"},{"key":"e_1_3_2_223_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00337-X"},{"key":"e_1_3_2_224_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00695-11"},{"key":"e_1_3_2_225_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1281-1288.2004"},{"key":"e_1_3_2_226_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1022-1025.2002"},{"key":"e_1_3_2_227_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2600-2603.2000"},{"key":"e_1_3_2_228_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.780-782.2004"},{"key":"e_1_3_2_229_2","first-page":"128","article-title":"A phase 1I study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee R","year":"2008","unstructured":"Rustomjee R Lienhardt C Kanyok T Davies GR Levin J Mthiyane T Reddy C Sturm AW Sirgel FA Allen J Coleman DJ Fourie B Mitchison DA . 2008. A phase 1I study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128\u2013138.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_230_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"e_1_3_2_231_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"e_1_3_2_232_2","doi-asserted-by":"publisher","DOI":"10.1038\/35016103"},{"key":"e_1_3_2_233_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2294-2301.2005"},{"key":"e_1_3_2_234_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"e_1_3_2_235_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.56"},{"key":"e_1_3_2_236_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05708-11"},{"key":"e_1_3_2_237_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki319"},{"key":"e_1_3_2_238_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"e_1_3_2_239_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00009509"},{"key":"e_1_3_2_240_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01297-10"},{"key":"e_1_3_2_241_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1189"},{"key":"e_1_3_2_242_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01182-08"},{"key":"e_1_3_2_243_2","volume-title":"AZD5847, an oxazolidinone for the treatment of tuberculosis: pre-clinical studies","author":"Balasubramanian V","year":"2011","unstructured":"Balasubramanian V Gaonkar S Solapure S Sambandamurthy V Shandil RK Mahesh KN Sharma S Kaur P Deepthi R Subbulakshmi V Ramya V Ramachandran V Reddy J Giridhar J Deshpande A Bharath S Kumar N Balganesh M Nandi V Wright L Melnick D . 2011. AZD5847, an oxazolidinone for the treatment of tuberculosis: pre-clinical studies. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr F1-1364."},{"key":"e_1_3_2_244_2","volume-title":"A 14 day multiple ascending dose study with AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB)","author":"Reele S","year":"2011","unstructured":"Reele S Xiao AJ Das S Balasubramanian V Melnick D . 2011. A 14 day multiple ascending dose study with AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB). Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr A1-1735."},{"key":"e_1_3_2_245_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.07.015"},{"key":"e_1_3_2_246_2","first-page":"75","article-title":"Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines","volume":"13","author":"Gerding DN","year":"2012","unstructured":"Gerding DN . 2012. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov. Med. 13:75\u201383.","journal-title":"Discov. Med."},{"key":"e_1_3_2_247_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis319"},{"key":"e_1_3_2_248_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051590"},{"key":"e_1_3_2_249_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00057-12"},{"key":"e_1_3_2_250_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06257-11"},{"key":"e_1_3_2_251_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201685h"},{"key":"e_1_3_2_252_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06305-11"},{"key":"e_1_3_2_253_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00867-12"},{"key":"e_1_3_2_254_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks359"},{"key":"e_1_3_2_255_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.12.012"},{"key":"e_1_3_2_256_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00471-11"},{"key":"e_1_3_2_257_2","volume-title":"Target- and resistance-based mechanistic studies with fluorocyclines TP-434 and TP-271","author":"Starosta AL","year":"2010","unstructured":"Starosta AL Fyfe C Wilson DN Sutcliffe J Grossman T . 2010. Target- and resistance-based mechanistic studies with fluorocyclines TP-434 and TP-271. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2160."},{"key":"e_1_3_2_258_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.660250"},{"key":"e_1_3_2_259_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.378521"},{"key":"e_1_3_2_260_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir167"},{"key":"e_1_3_2_261_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2010.02660.x"}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00033-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00033-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:19:05Z","timestamp":1645600745000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.00033-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":260,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1128\/CMR.00033-13"],"URL":"https:\/\/doi.org\/10.1128\/cmr.00033-13","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"2013-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}